Michael G. Fradley

Cardiovascular Risk of First and Second Generation Bruton’s Tyrosine Kinase Inhibitors: A Systematic Review and Network Meta-Analysis

Hardil Anup Bhatt, Ibrahim AlQassas, Farid Foroutan, Rachel Lu et autres

Abstract Aims Ibrutinib increases cardiovascular adverse events, but the comparative cardiovascular safety of second-generation Bruton’s tyrosine kinase inhibitors (BTKi) remains uncertain. We compared cardiovascular adverse events among ibrutinib, acalabrutinib, zanubrutinib, and non-BTKi therapies. Methods and Results We conducted a systematic review and …

ca, rs, us (code pays fourni par la source)

Cardiac Monitoring for Patients Undergoing Treatment With MEK Inhibitor Monotherapy

Jondavid Menteer, Devorah Segal, Stefania Maraka, Laura J. Klesse et autres

PURPOSE OF REVIEW: Aberrant activation of the RAS-RAF-MEK-ERK signaling pathway contributes to numerous malignancies, congenital syndromes, and cardiovascular disorders, establishing MEK inhibitors (MEKi) as crucial therapeutic agents. MEKi demonstrate substantial clinical benefit as monotherapy (e.g., NF1-associated tumors) or combination therapy (e.g., melanoma, …

us (code pays fourni par la source)

Mid‐ and Long‐Term Risk of Venous Thromboembolism Among Female Breast Cancer Survivors: A Nationwide Cohort Study

Jihun Kang, Wonyoung Jung, Bongseong Kim, Hyeonjin Cho et autres

Venous thromboembolism (VTE) is a serious complication for breast cancer (BC) survivors. We identified records of female BC survivors from the Korean Health Insurance Service database between January 1, 2010, and December 31, 2016. After applying exclusion criteria (age < 18 years, …

us, kr (code pays fourni par la source)

Radiomics for the Detection and Prediction of Cancer Therapy-Related Cardiotoxicity

Abhinav Kandala, Amar Rai, Rahul Penumaka, Nicholas S. Wilcox et autres

Modern cancer therapies have improved survival but unmasked the growing challenge of cancer therapy-related cardiotoxicity, a leading cause of morbidity and mortality in cancer survivors. Current surveillance strategies, relying on serial echocardiography and cardiac biomarkers, are reactive, detecting cardiac injury only after …

gb, us (code pays fourni par la source)

Time-Dependent Association Between Breast Cancer and Risk of Ischemic Stroke

Yong‐Moon Park, Wonyoung Jung, Bongseong Kim, Minwoo Lee et autres

BACKGROUND AND OBJECTIVES: The association between breast cancer diagnosis and treatment and the risk of incident ischemic stroke remains unclear. We investigated ischemic stroke risk among breast cancer survivors and evaluated associations by age, follow-up duration, and type of cancer treatment. METHODS: …

us, kr (code pays fourni par la source)

Atrial Fibrillation Risk and Cardiovascular Events After Hematopoietic Cell Transplantation

Robert Monsour, Kyunga Ko, Amanda M. Smith, Benedicte Lefebvre et autres

[Figure: see text]

us (code pays fourni par la source)

Cardiovascular Adverse Events During Venetoclax‐Based Treatment in Acute Myeloid Leukemia

Sruthi Selvakumar, Sanath Shetty, A. Sharma, Fatima Tuz Zahra et autres

Background Venetoclax, a potent B‐cell leukemia/lymphoma‐2 inhibitor, is an antineoplastic agent used in various hematologic malignancies, including acute myeloid leukemia (AML). The aim of the study is to evaluate the incidence, risk factors, and outcomes of major adverse cardiac events (MACEs) among …

us (code pays fourni par la source)

Abstract 884: Waist-hip ratio (WHR) defined obesity phenotype and risk of diabetes in cancer survivor women from Sister Study.

Mahfuja Luna, Hazel B. Nichols, Katie M. O'Brien, Michael G. Fradley et autres

Abstract Introduction: Cancer survivors are at elevated risk of developing diabetes and often experience treatment-related changes in body composition and insulin sensitivity. However, few studies have evaluated whether general and central obesity, independently and jointly, are associated with diabetes risk in long-term …

us (code pays fourni par la source)

Arrhythmias and cardiac devices management in oncology patients

Estelle Torbey, Jim W. Cheung, Zain Ul Abideen Asad, Kamala P. Tamirisa et autres

Cardiac arrhythmia is increasingly encountered in patients with cancer, not only as a result of shared risk factors but also as a direct consequence of malignancy and its therapies. This evolving overlap has positioned arrhythmia management as a key component of cardio-oncology …

us, gb (code pays fourni par la source)

26-A-14008-ACC RADIOMICS FOR THE DETECTION AND PREDICTION OF CARDIOTOXICITY IN PATIENTS WITH CANCER: A STRUCTURED NARRATIVE REVIEW

Abhinav Kandala, Amar K. Rai, Rahul Penumaka, Nicholas S. Wilcox et autres

gb, us (code pays fourni par la source)

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Abdelrahman Ali, Suparna C. Clasen, Anne Blaes, Stephen Casselli et autres

INTRODUCTION AND METHODS: Cancer therapy-related cardiac dysfunction (CTRCD) is a well established and potentially life-threatening complication of contemporary oncologic treatment. Although comprehensive cardio-oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent. This consensus statement, developed by …

us, be, es, cn, au, gb, sg (code pays fourni par la source)

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi et autres

Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship …

us (code pays fourni par la source)